NCG-MHC-dKO Mice Details
The NCG-MHC-dKO is a triple immunodeficient NCG mouse that lacks expression of the MHC class I molecule (H2-K and H2-D1), and MHC class II molecule (H2-Ab1). Lack of expression of MHC I and MHC II leads to a significant delay in the onset of graft-versus-host disease (GVHD) in PBMC humanized NCG models.
Origin
The NCG mouse strain was co-developed by Nanjing Biomedical Research Institute of Nanjing University and Nanjing Galaxy Biopharma in 2014 and transferred to CRL in 2016. Nanjing Galaxy Biopharma became Gempharmatech in 2019, while retaining oversight of the original NCG colony. GPT later modified the original NCG strain by knocking out MHC I and II expression creating the NCG-MHC-dKO. The strain was transferred to Charles River in 2023.
This weight chart is to be used as reference only.
LOCATION: Raleigh
UNIT: R04I
Download the Report
➤ DOWNLOAD OUR CATALOG for instant access to Standard List Pricing
➤ TALK TO US to discuss organization or volume-based discounts
Try out this model with our animal evaluation program
Immunodeficient Model Selection Poster
Compare immune cell deficits (T/B/NK), engraftment applications, and practical study considerations (e.g., leakiness and radiation tolerance) side-by-side across multiple immunodeficient mouse and rat models. Download Poster
Resources
WEBINAR
Advance Your Oncology and Immunology Research with Next-Generation Mouse Models
Learn how NCG immunodeficient and humanized mouse models advance oncology and immunology research, accelerating predictive humanized and PDX applications. Watch on Demand